234 related articles for article (PubMed ID: 26629687)
21. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
22. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
Date I; Asari S; Nishimoto A; Felten DL
No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347
[TBL] [Abstract][Full Text] [Related]
23. Preventive role of PD-1 on MPTP-induced dopamine depletion in mice.
Jung HW; Son HY; Jin GZ; Park YK
Cell Biochem Funct; 2010 Apr; 28(3):217-23. PubMed ID: 20186864
[TBL] [Abstract][Full Text] [Related]
24. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
25. siRNA-mediated knockdown of B3GALT4 decreases GM1 ganglioside expression and enhances vulnerability for neurodegeneration.
Verma M; Schneider JS
Mol Cell Neurosci; 2019 Mar; 95():25-30. PubMed ID: 30611881
[TBL] [Abstract][Full Text] [Related]
26. The Key Role of GM1 Ganglioside in Parkinson's Disease.
Chowdhury S; Ledeen R
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204675
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
[TBL] [Abstract][Full Text] [Related]
28. Naringin treatment induces neuroprotective effects in a mouse model of Parkinson's disease in vivo, but not enough to restore the lesioned dopaminergic system.
Kim HD; Jeong KH; Jung UJ; Kim SR
J Nutr Biochem; 2016 Feb; 28():140-6. PubMed ID: 26878791
[TBL] [Abstract][Full Text] [Related]
29. Membrane carbohydrate conjugates desialylation does not alter [3H]-dopamine uptake in rat striatal slices.
Page G; Barrier L; Fauconneau B; Piriou A; Tallineau C; Huguet F
Neurosci Lett; 1998 Oct; 255(3):139-42. PubMed ID: 9832192
[TBL] [Abstract][Full Text] [Related]
30. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
Wu G; Lu ZH; Kulkarni N; Ledeen RW
J Neurosci Res; 2012 Oct; 90(10):1997-2008. PubMed ID: 22714832
[TBL] [Abstract][Full Text] [Related]
31. The neuroprotective effect of modified Yeoldahanso-tang via autophagy enhancement in models of Parkinson's disease.
Bae N; Ahn T; Chung S; Oh MS; Ko H; Oh H; Park G; Yang HO
J Ethnopharmacol; 2011 Mar; 134(2):313-22. PubMed ID: 21172413
[TBL] [Abstract][Full Text] [Related]
32. Anti-inflammatory role of GM1 and other gangliosides on microglia.
Galleguillos D; Wang Q; Steinberg N; Zaidi A; Shrivastava G; Dhami K; Daskhan GC; Schmidt EN; Dworsky-Fried Z; Giuliani F; Churchward M; Power C; Todd K; Taylor A; Macauley MS; Sipione S
J Neuroinflammation; 2022 Jan; 19(1):9. PubMed ID: 34991625
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
34. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
35. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease.
Li H; He Z; Su T; Ma Y; Lu S; Dai C; Sun M
Neurol Res; 2003 Apr; 25(3):263-7. PubMed ID: 12739234
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
37. Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside.
Wu G; Lu ZH; Seo JH; Alselehdar SK; DeFrees S; Ledeen RW
Exp Neurol; 2020 Jul; 329():113284. PubMed ID: 32165255
[TBL] [Abstract][Full Text] [Related]
38. Differential accumulation of gangliosides by the brains of MPTP-lesioned mice.
Saulino MF; Schengrund CL
J Neurosci Res; 1994 Feb; 37(3):384-91. PubMed ID: 8176760
[TBL] [Abstract][Full Text] [Related]
39. Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.
Binukumar BK; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
Mol Biol Cell; 2015 Dec; 26(24):4478-91. PubMed ID: 26399293
[TBL] [Abstract][Full Text] [Related]
40. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
